Acetaminophen as Renoprotective Treatment in a Patient With Severe Malaria.

Joshua Shultz, Marina Antar-Shultz, Jorge Antonio Lamarche, Panagiotis Zervogiannis, Mohamed Taha
{"title":"Acetaminophen as Renoprotective Treatment in a Patient With Severe Malaria.","authors":"Joshua Shultz,&nbsp;Marina Antar-Shultz,&nbsp;Jorge Antonio Lamarche,&nbsp;Panagiotis Zervogiannis,&nbsp;Mohamed Taha","doi":"10.12788/fp.0355","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Severe falciparum malaria with renal impairment carries a significant risk of poor outcomes, including death. Previous randomized controlled trials using acetaminophen as adjunctive treatment for malaria-associated renal failure have demonstrated improvements in renal function and kidney injury progression.</p><p><strong>Case presentation: </strong>A 50-year-old man with severe falciparum malaria presented with hemolytic anemia, oliguric acute kidney injury, nephrotic range proteinuria, and significant architectural changes on renal ultrasound. Treatment with oral acetaminophen 975 mg every 6 hours was based on the randomized controlled trial protocol to salvage his renal function and avoid dialysis. During the acetaminophen course, urine output and cystatin C level improved with only mild, asymptomatic elevations in aminotransferases that were corrected on follow-up. The patient recovered without requiring dialysis.</p><p><strong>Conclusions: </strong>Acetaminophen's potential to mitigate the oxidative damage of hemoproteins suggests its use as a treatment in severe malaria with renal impairment.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 3","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204929/pdf/fp-40-03-e0355.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/fp.0355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Severe falciparum malaria with renal impairment carries a significant risk of poor outcomes, including death. Previous randomized controlled trials using acetaminophen as adjunctive treatment for malaria-associated renal failure have demonstrated improvements in renal function and kidney injury progression.

Case presentation: A 50-year-old man with severe falciparum malaria presented with hemolytic anemia, oliguric acute kidney injury, nephrotic range proteinuria, and significant architectural changes on renal ultrasound. Treatment with oral acetaminophen 975 mg every 6 hours was based on the randomized controlled trial protocol to salvage his renal function and avoid dialysis. During the acetaminophen course, urine output and cystatin C level improved with only mild, asymptomatic elevations in aminotransferases that were corrected on follow-up. The patient recovered without requiring dialysis.

Conclusions: Acetaminophen's potential to mitigate the oxidative damage of hemoproteins suggests its use as a treatment in severe malaria with renal impairment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对乙酰氨基酚对重症疟疾患者肾保护作用的研究。
背景:伴有肾脏损害的严重恶性疟疾具有显著的不良预后风险,包括死亡。先前的随机对照试验使用对乙酰氨基酚作为疟疾相关性肾衰竭的辅助治疗,已经证明了肾功能和肾损伤进展的改善。病例介绍:一名50岁男性重症恶性疟疾患者,表现为溶血性贫血,少尿急性肾损伤,肾病范围蛋白尿,肾脏超声检查有明显的结构改变。根据随机对照试验方案,每6小时口服对乙酰氨基酚975 mg,以挽救其肾功能并避免透析。在对乙酰氨基酚治疗过程中,尿量和胱抑素C水平有所改善,只有轻微的、无症状的转氨酶升高,在随访中得到纠正。病人不需要透析就康复了。结论:对乙酰氨基酚减轻血红蛋白氧化损伤的潜力表明其可用于治疗严重疟疾伴肾损害。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Olfactory Hallucinations Following COVID-19 Vaccination. Oropharyngeal Squamous Cell Carcinoma Outcomes by p16INK4a Antigen Status in a Veteran Population. Outcomes in Patients With Curative Malignancies Receiving Filgrastim as Primary Prophylaxis. Contralateral Constrictor Dose Predicts Swallowing Function After Radiation for Head and Neck Cancer. Acute Painful Horner Syndrome as the First Presenting Sign of Carotid Artery Dissection.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1